MedTrace Logo

Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer

NCT00002881 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2010-11-09

No results posted yet for this study

Summary

RATIONALE: Hormone therapy may be an effective treatment for prostate cancer.

PURPOSE: Randomized phase III trial to evaluate the effectiveness of treatment with flutamide and suramin with or without hydrocortisone in men who have metastatic or recurrent prostate cancer.

Conditions

Interventions

DRUG

flutamide

DRUG

goserelin acetate

DRUG

leuprolide acetate

DRUG

suramin

DRUG

therapeutic hydrocortisone

PROCEDURE

orchiectomy

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Cancer and Leukemia Group B

    collaborator NETWORK

  • SWOG Cancer Research Network

    collaborator NETWORK

  • Eastern Cooperative Oncology Group

    lead NETWORK

Principal Investigators

  • George Wilding, MD · University of Wisconsin, Madison

  • Nancy A. Dawson, MD · Walter Reed Army Medical Center

  • A. O. Sartor, MD · Louisiana State University Health Sciences Center in New Orleans

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-10-31
Primary Completion
1998-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002881 on ClinicalTrials.gov